Ozmosi | UMN-0501 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

UMN-0501

Alternative Names: umn-0501, umn0501, umn 0501
Clinical Status: Inactive
Latest Update: 2024-03-07
Latest Update Note: PubMed Publication

Product Description

UMN's pandemic influenza vaccine. (Sourced from: https://www.umnpharma.com/en/release/irnews/irnews4494115710593199842.html)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: UMN Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Influenza, Human|Influenza in Birds

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT01195038

 JPIP501-01b

P2

Completed

Influenza in Birds|Influenza, Human

2011-01-01

2019-03-19

Treatments

NCT00980447

 JPIP501-01a

P2

Completed

Influenza in Birds|Influenza, Human

2009-12-01

2019-03-19

Recent News Events

Date

Type

Title

03/07/2024

PubMed

 Flublok Quadrivalent Vaccine Adjuvanted with R-DOTAP Elicits a Robust and Multifunctional CD4 T Cell Response That Is of Greater Magnitude and Functional Diversity Than Conventional Adjuvant Systems.

12/21/2023

PubMed

 Whole Blood Reactivity to Viral and Bacterial Pathogens after Non-Emergent Cardiac Surgery during the Acute and Convalescence Periods Demonstrates a Distinctive Profile of Cytokines Production Compared to the Preoperative Baseline in Cohort of 108 Patients, Suggesting Immunological Reprogramming during the 28 Days Traditionally Recognized as the Post-Surgical Recovery Period.

12/14/2023

PubMed

 Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions